MAOB and Parkinson disease: Safinamide, a third MAO-B inhibitor, is used as an adjuvant therapy or as a dopamine agonist in conjunction with levodopa, and it combines additional non-dopaminergic qualities that may be beneficial for patients with PD (Figure 2) [12,13,14].